This site is intended for healthcare professionals
Drug news

CHMP recommends radium Ra 223 dichloride for Prostate Cancer

Read time: 1 mins
Last updated:22nd Sep 2013
Published:22nd Sep 2013
Source: Pharmawand

Bayer HealthCare has announced that the European Committee for Medicinal Products for Human Use (CHMP) has on 20 September 2013, recommended radium Ra 223 dichloride (radium-223) for approval with a proposed indication for the treatment of adults with castration-resistant Prostate Cancer, symptomatic bone metastases and no known visceral metastases. The CHMP recommendation is based on data from the pivotal Phase III ALSYMPCA (ALpharadin in SYMptomatic Prostate CAncer) trial. The decision of the European Commission on the approval is expected in the fourth quarter of 2013.

Radium-223 was approved by the FDA in May under the brand name Xofigo.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.